The overall goals ofthe program project grant (PPG) and individual projects require primary human cells from the two human subjects protocols described in Core A (Clinical Core). The goal of Core B (Laboratory Core) is to process the clinical samples from the human subjects protocols to provide high quality cells to each project for planned in vitro experiments and future analysis of clinical samples. Specific Task 1: Isolate purified eosinophils (EOS) and other cell populations from peripheral blood donors. Subjects that have been well characterized by Core A (Clinical Core) for the blood donor protocol will be recruited for peripheral blood donation. Using gradient centrifugation and magnetic bead negative separation techniques, purified EOS and/or other cell types (e.g. monocytes and CD4^ T cells) will be prepared for in vitro experimental use by the PPG projects. Spcicific Task 2: Process bronchoalveolar lavage (BAL) samples to isolate EOS and other cell populations. BAL fluid derived from subjects enrolled in the Core A (Clinical Core) protocol will be collected. Using gradient centrifugation and other cell separation techniques, purified EOS and/or other cell types (e.g. monocytes and T cells) will be prepared for in vitro experimental use by the PPG projects. Specific Task 3: Adapt current protocols to the requirements of each project. Any ofthe protocols in the first two tasks and other EOS functional assays will be adapted for the needs of any project.
The relevance ofthe Laboratory Core is to provide critical and high quality purified EOS from blood and BAL as well as monocytes, 004"" T cells, and neutrophils from blood to the three projects to interrogate the role of EOS in airway remodeling associated with asthma.
|Wilkerson, Emily M; Johansson, Mats W; Hebert, Alexander S et al. (2016) The Peripheral Blood Eosinophil Proteome. J Proteome Res 15:1524-33|
|Shen, Zhong-Jian; Hu, Jie; Shiizaki, Kazuhiro et al. (2016) Phosphate-Induced Renal Fibrosis Requires the Prolyl Isomerase Pin1. PLoS One 11:e0150093|
|Esnault, Stephane; Johansson, Mats W; Kelly, Elizabeth A et al. (2016) IL-3 Up-regulates and Activates Human Eosinophil CD32 and Î±MÃŸ2 Integrin Causing Degranulation. Clin Exp Allergy :|
|Olson, Ashleigh A; Evans, Michael D; Johansson, Mats W et al. (2016) Role of food and aeroallergen sensitization in eosinophilic esophagitis in adults. Ann Allergy Asthma Immunol 117:387-393.e2|
|Mathur, Sameer K; Fichtinger, Paul S; Evans, Michael D et al. (2016) Variability of blood eosinophil count as an asthma biomarker. Ann Allergy Asthma Immunol 117:551-553|
|Esnault, Stephane; Kelly, Elizabeth A; Sorkness, Ronald L et al. (2016) Airway factor XIII associates with type 2 inflammation and airway obstruction in asthmatic patients. J Allergy Clin Immunol 137:767-73.e6|
|Zheng, M; Turton, K B; Zhu, F et al. (2016) A mix of S and Î”S variants of STAT3 enable survival of activated B-cell-like diffuse large B-cell lymphoma cells in culture. Oncogenesis 4:e184|
|Kelly, Elizabeth A; Esnault, Stephane; Johnson, Sean H et al. (2016) Human eosinophil activin A synthesis and mRNA stabilization are induced by the combination of IL-3 plus TNF. Immunol Cell Biol 94:701-8|
|Metcalfe, Dean D; Pawankar, Ruby; Ackerman, Steven J et al. (2016) Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organ J 9:7|
|Shen, Zhong-Jian; Malter, James S (2015) XBP1, a determinant of the eosinophil lineage. Nat Immunol 16:793-4|
Showing the most recent 10 out of 79 publications